Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck-Reference-Cited by-同舟云学术

Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck

Published:2009-10 Issue:10 Volume:45 Page:e155-e160
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Cohen Ezra Eddy Wyssam,Halpern Anna B.,Kasza Kristen,Kocherginsky Masha,Williams Rosalyn,Vokes Everett E.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference20 articles.

1. The expanding role of systemic therapy in head and neck cancer;Cohen;J Clin Oncol,2004

2. Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors;Ahmed;Curr Cancer Drug Targets,2007

3. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck;Cohen;J Clin Oncol,2006

4. EGFR inhibitors: what have we learned from the treatment of lung cancer?;Giaccone;Nat Clin Pract Oncol,2005

5. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR;Cohen;Clin Cancer Res,2005

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic application of extracellular vesicular EGFR isoform D as a co-drug to target squamous cell cancers with tyrosine kinase inhibitors;Developmental Cell;2024-08

2. Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status;Frontiers in Oncology;2022-08-30

3. More than a Bubble: Extracellular Vesicle microRNAs in Head and Neck Squamous Cell Carcinoma;Cancers;2022-02-24

4. How to Achieve Therapeutic Response in Erlotinib-Resistant Head and Neck Squamous Cell Carcinoma? New Insights from Stable Isotope Labeling with Amino Acids in Cell Culture-Based Quantitative Tyrosine Phosphoproteomics;OMICS: A Journal of Integrative Biology;2021-09-01

5. Identification of extracellular vesicles-transported miRNAs in Erlotinib-resistant head and neck squamous cell carcinoma;Journal of Cell Communication and Signaling;2020-03-10